Newsroom
Teleflex Incorporated (TFX) Reports Strong Q2 2024 Earnings and Raises Profit Forecast
By KlickAnalytics Data Insights | August 1, 2024 08:08PM ET
Key Points
- Teleflex (TFX) Q2 earnings of $3.42 per share beat estimates
- Company raises 2024 profit forecast on strong medical device demand
- Quarterly dividend of $0.34 per share declared by the Board of Directors
- Teleflex announces $500 million share repurchase authorization
- Q2 financial results show positive outlook for full year 2024
Teleflex Incorporated (NYSE: TFX) recently held its Q2 2024 Earnings Conference Call on August 1, 2024, where Vice President-Investor Relations & Strategy Development, Lawrence Keusch, along with Chairman, President & CEO Liam Kelly and Executive Vice President & CFO Thomas Powell discussed the company's performance. The call included various conference call participants from notable groups such as Mizuho Group, Piper Sandler, and Raymond James.
During the call, it was revealed that Teleflex (TFX) reported quarterly earnings of $3.42 per share, surpassing the Zacks Consensus Estimate of $3.33 per share. This marked an improvement from the $3.41 per share earnings reported in the same quarter last year, indicating positive growth for the company.
One key highlight from the conference call was Teleflex's decision to raise its 2024 profit forecast, citing strong demand for certain surgical procedures at hospitals as a driving factor for sales of its medical devices. This move reflects the company's confidence in its ability to capitalize on market opportunities and meet financial targets for the year.
In addition to the strong financial performance, Teleflex announced a quarterly cash dividend of $0.34 per share of common stock. The dividend is set to be payable on September 16, 2024, to shareholders of record as of August 15, 2024. This dividend declaration demonstrates the company's commitment to creating value for its shareholders through consistent returns.
Furthermore, Teleflex revealed its plans for a $500 million share repurchase authorization, which includes a $200 million accelerated share repurchase of common stock. This strategic move aims to enhance shareholder value and signal the company's confidence in its long-term growth trajectory.
Overall, Teleflex's second-quarter financial results and the positive outlook for full year 2024 indicate a strong performance in the medical devices sector. The company's ability to surpass earnings estimates, raise profit forecasts, declare dividends, and announce share repurchase authorizations are all positive indicators of its financial health and growth potential in the market.
For more information:
Ask the market a question. Get a calculated answer.
The AI is not a chatbot bolted onto a document store. It calls the same analytics engine that powers every screen on this platform — so what comes back is a number it computed from raw history, with the command that produced it.
86,000+ instruments
Global equities, ETFs, funds, options, FX, commodities, crypto, economics, filings, transcripts and news — one normalised symbol universe with adjusted history.
A real analytics engine
Screening, backtesting, technicals, options analytics, correlations, seasonality and factor models — computed on demand from raw prices, never a stale cache.
It shows its working
Answers arrive with the charts, tables and tool calls behind them, so you can check the number instead of trusting a paraphrase.
Your own documents
Upload filings, decks and research. Ask across them and the answer cites the page it came from.
Agents and workflows
Multi-step research that runs the platform's tools for you — screen, pull the history, compute, compare, then write it up.
MCP, CLI and API
The same command catalogue from Claude, your own agent, a shell or your pipeline. The answer on screen is the answer your job gets at 4am.
You ask
“How does NVDA usually trade through earnings?”
It calls
→ ka.options_expected_move(NVDA)
It answers
NVDA has averaged a 9.2% absolute move on the day after earnings and closed higher 67% of the time. Two in three reactions land between −4.2% and +16.3% — the distribution is skewed right, not symmetric.
Every figure computed live from our own history — not scraped, not summarised.
Or start with